Microbot Medical Inc.
MBOT
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Microbot Medical develops and tests medical robotic systems, including its LIBERTY Endovascular Robotic System, which is designed for surgical procedures. The company's product development pipeline relies on animal testing, as evidenced by its completion of a Good Laboratory Practice (GLP) animal study for the LIBERTY system in 2022. The company's own SEC filings explicitly identify unsuccessful animal studies as a material risk to its business, confirming that animal testing is an integral and ongoing component of its research and development activities. This reliance places the company within the scope of commercial animal exploitation for product development.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.